VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Males and females who are at least 18 years of age │ Males and females who are at least 18 years of age │     100 │
│ at time of enrollment                              │ at time of enrollment                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject understands the investigational nature of  │ Subject understands the investigational nature of  │     100 │
│ the study and provides written, informed consent   │ the study and provides written, informed consent   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects taking any lipid modification therapy,    │ Subjects taking any lipid modification therapy,    │     100 │
│ including but not limited to statins, fibrates and │ including but not limited to statins, fibrates and │         │
│ bile acid sequestrants                             │ bile acid sequestrants                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects taking fish oil or any other supplements, │ Subjects taking fish oil or any other supplements, │     100 │
│ which in the investigator s opinion may interfere  │ which in the investigator s opinion may interfere  │         │
│ with the study                                     │ with the study                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with acute liver disease or active peptic │ Subjects with acute liver disease or active peptic │     100 │
│ ulcer disease                                      │ ulcer disease                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with elevated uric acid levels greater    │ Subjects with elevated uric acid levels greater    │     100 │
│ than 10 mg/dL or gout                              │ than 10 mg/dL or gout                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or women currently breastfeeding         │ Pregnancy or women currently breastfeeding         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects taking hormonal contraceptives or  │ Female subjects taking hormonal contraceptives or  │     100 │
│ hormone replacement therapy may be included in     │ hormone replacement therapy may be included in     │         │
│ this study only if they have been on a stable dose │ this study only if they have been on a stable dose │         │
│ for at least 3 months                              │ for at least 3 months                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI less than 18.5                                 │ BMI less than 18.5                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with weight that varies greater than 20%  │ Subjects with weight that varies greater than 20%  │     100 │
│ over the past 3 months                             │ over the past 3 months                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects taking the following medications for at   │ Subjects taking the following medications for at   │     100 │
│ least six weeks, which may interfere with the      │ least six weeks, which may interfere with the      │         │
│ study, will be excluded: BAS, antibiotics,         │ study, will be excluded: BAS, antibiotics,         │         │
│ anticoagulants, anticonvulsants, antiarrhythmic,   │ anticoagulants, anticonvulsants, antiarrhythmic,   │         │
│ Cyclosporine, Mycophenolate and Synthroid.         │ Cyclosporine, Mycophenolate and Synthroid.         │         │
│ Subjects with chronic diarrhea, gastric bypass or  │ Subjects with chronic diarrhea, gastric bypass or  │         │
│ lap band procedures, ostomies, bowel motility      │ lap band procedures, ostomies, bowel motility      │         │
│ problems, or other conditions that could affect    │ problems, or other conditions that could affect    │         │
│ intestinal fat absorption                          │ intestinal fat absorption                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects initiating new medications or patients on │ Subjects initiating new medications or patients on │     100 │
│ multiple medications may also be excluded          │ multiple medications may also be excluded          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to swallow capsules                      │ Inability to swallow capsules                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of type I or type II       │ Patients with a history of type I or type II       │     100 │
│ diabetes or HbA1c greater than 6.5%                │ diabetes or HbA1c greater than 6.5%                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Volunteers may also be excluded, if in the opinion │ Volunteers may also be excluded, if in the opinion │     100 │
│ of the study investigators, they have some other   │ of the study investigators, they have some other   │         │
│ condition or disorder that may adversely affect    │ condition or disorder that may adversely affect    │         │
│ the outcome of the study or the safety of the      │ the outcome of the study or the safety of the      │         │
│ volunteer                                          │ volunteer                                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Subjects with acute liver disease or active peptic │      37 │
│                                   │ ulcer disease                                      │         │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 99 Years │ Subjects with acute liver disease or active peptic │      37 │
│                                   │ ulcer disease                                      │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 92.58823529411765
OverAll Ratio: 95.29411764705883
